Royalty Pharma plc Files 8-K for Material Definitive Agreement

Ticker: RPRX · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1802768

Royalty Pharma PLC 8-K Filing Summary
FieldDetail
CompanyRoyalty Pharma PLC (RPRX)
Form Type8-K
Filed DateJun 4, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $500 million
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, 8-k

TL;DR

Royalty Pharma just signed a big deal, filing an 8-K today.

AI Summary

On June 3, 2024, Royalty Pharma plc entered into a material definitive agreement. The company, headquartered at 110 East 59th Street, New York, NY, filed an 8-K report detailing this agreement. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates a significant new contract or partnership for Royalty Pharma, which could impact its future revenue streams and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new financial risks or opportunities, the specifics of which are not yet detailed in this initial filing.

Key Players & Entities

FAQ

What type of material definitive agreement did Royalty Pharma plc enter into?

The filing states that Royalty Pharma plc entered into a material definitive agreement, but the specific nature of the agreement is not detailed in the provided excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on June 3, 2024.

What is the principal executive office address for Royalty Pharma plc?

The principal executive office address for Royalty Pharma plc is 110 East 59th Street, New York, New York 10022.

What is the telephone number for Royalty Pharma plc?

The telephone number for Royalty Pharma plc is (212) 883-0200.

What is the Commission File Number for Royalty Pharma plc?

The Commission File Number for Royalty Pharma plc is 001-39329.

Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-06-04 16:57:02

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit 1.1 Underwriting Agreement, dated as of June 3, 2024, by and among Royalty Pharma plc, Royalty Pharma Holdings Ltd, RP Management, LLC and the underwriters named therein. Exhibit 104 Cover Page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 ROYALTY PHARMA PLC By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing